Role of kidney ADP-ribosyl cyclase in diabetic nephropathy

American Journal of Physiology - Renal Physiology

Volumn 296, Issue 2, 2009, Pages

  Kim, Seon Young ^a   Park, Kwang Hyun ^a   Gul, Rukhsana ^a   Jang, Kyu Yoon ^a   Kim, Uh Hyun ^a  

^a Chonbuk National University Medical School   (South Korea)

Author keywords

4,4 dihydroxyazobenzene; Angiotensin; CADP ribose

Indexed keywords

4,4' DIHYDROXYAZOBENZENE; ADENOSINE DIPHOSPHATE RIBOSYL CYCLASE; ALBUMIN; ANGIOTENSIN II; ANTIDIABETIC AGENT; CREATININE; PROTEIN KINASE B; TRANSCRIPTION FACTOR NFAT3; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BODY WEIGHT; CONTROLLED STUDY; CREATININE CLEARANCE; DIABETIC NEPHROPATHY; DRUG EFFECT; DRUG INHIBITION; ENZYME ACTIVITY; ENZYME PHOSPHORYLATION; KIDNEY FUNCTION; KIDNEY HYPERTROPHY; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; STREPTOZOCIN DIABETES;

EID: 60549096724     PISSN: 1931857X     EISSN: 15221466     Source Type: Journal    
DOI: 10.1152/ajprenal.90381.2008     Document Type: Article

References (36)

1. Anderson S, Jung FF, Inglefinger JR. Renal renin-angiotensin system in diabetes: functional, immunohistochemical, and molecular biological correlations. Am J Physiol Renal Fluid Electrolyte Physiol 265: F477-F486, 1993.
2. Barbosa MT, Soares SM, Novak CM, Sinclair D, Levine JA, Aksoy P, Chini EN. The enzyme CD38 (a NAD glycohydrolase, EC 3225) is necessary for the development of diet-induced obesity. FASEB J 21: 3629-3639, 2007.
3. Barnett AH, Bain SC, Bouter P, Karlberg B, Madsbad S, Jervell J, Mustonen J. Angiotensin-receptor blockade versus converting-enzyme inhibition in type 2 diabetes and nephropathy. N Engl J Med 351: 1952-1961, 2004.
4. Chen S, Hong SW, Iglesias-de la Cruz MC, Isono M, Casaretto A, Ziyadeh FN. The key role of the transforming growth factor-beta system in the pathogenesis of diabetic nephropathy. Renal Fail 23: 471-481, 2001.
5. Cooper ME. Interaction of metabolic and haemodynamic factors in mediating experimental diabetic nephropathy. Diabetologia 44: 1957-1972, 2001.
6. Galione A, Churchill GC. Cyclic ADP-ribose as a calcium-mobilizing messenger. Sci STKE 41: pe1, 2000.
7. Graeff RM, Walseth TF, Fryxell K, Branton WD, Lee HC. Enzymatic synthesis and characterizations of cyclic GDP-ribose. A procedure for distinguishing enzymes with ADP-ribosyl cyclase activity. J Biol Chem 269: 30260-30267, 1994.
8. Gul R, Kim SY, Park KH, Kim BJ, Kim SJ, Im MJ, Kim UH. A novel signaling pathway of ADP-ribosyl cyclase activation by angiotensin II in adult rat cardiomyocytes. Am J Physiol Heart Circ Physiol 295: H77-H88, 2008.
9. Guse AH, Silva CP, Berg I, Skapenko AL, Weber K, Heyer P, Hohenegger M, Pitter BV, Mayr GW. Regulation of calcium signalling
10. in T lymphocytes by the second messenger cyclic ADP-ribose. Nature 398: 70-73, 1999.
11. Hartner A, Cordasic N, Klanke B, Wittmann M, Veelken R, Hilgers KF. Renal injury in streptozotocin-diabetic Ren2-transgenic rats is mainly dependent on hypertension, not on diabetes. Am J Physiol Renal Physiol 292: F820-F827, 2007.
12. Higashida H, Zhang JS, Hashi M, Shintaku M, Higashida C, Takeda Y. Angiotensin II stimulates cyclic ADP-ribose formation in neonatal rat cardiac myocytes. Biochem J 352: 197-202, 2000.
13. Hong CY, Chia KS. Markers of diabetic nephropathy. J Diabetes Complications 12: 43-60, 1998.
14. Horsley V, Pavlath GK. NFAT: ubiquitous regulator of cell differentiation and adaptation. J Cell Biol 156: 771-774, 2002.
15. Institute of Laboratory Animal Research, Commission of Life Sciences, National Research Council. Guide for the Care and Use of Laboratory Animals. Washington, DC, National Academy Press, 1996.
16. 2+ signal that is essential for insulin secretion in mouse pancreatic islets. Diabetes 57: 868 -878, 2008.
17. Kim SY, Gul R, Rah SY, Kim SH, Park SK, Im MJ, Kwon HJ, Kim UH. Molecular mechanism of ADP-ribosyl cyclase activation in angiotensin II signaling in murine mesangial cells. Am J Physiol Renal Physiol 294: F982-F989, 2008.
18. Kim UH, Han MK, Park BH, Kim HR, An NH. Function of NAD glycohydrolase in ADP-ribose uptake from NAD by human erythrocytes. Biochim Biophys Acta 1178: 121-128, 1993.
19. Krajka-Kuzniak V, Baer-Dubowska W. The effects of tannic acid on cytochrome P450 and phase II enzymes in mouse liver and kidney. Toxicol Lett 143, 209-216, 2003.
20. Lewis EJ, Hunsicker LG, Bain RP. The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The Collaborative Study Group. N Engl J Med 329: 1456-1462, 1993.
21. Liu Y. Renal fibrosis: new insights into the pathogenesis and therapeutics. Kidndy Int 69: 213-217, 2006.
22. Makino H, Miyamoto Y, Sawai K, Mori K, Mukoyama M, Nakao K, Yoshimasa Y, Suga SI. Altered gene expression related to glomerulogenesis and podocyte structure in early diabetic nephropathy of db/db mice and its restoration by pioglitazone. Diabetes 55: 2747-2756, 2006.
23. Mehta K, Shahid U, Malavasi F. Human CD38, a cell-surface protein with multiple functions. FASEB J 10: 1408-1417, 1996.
24. Mezzano SA, Ortega MR, Egido J. Angiotensin II and renal fibrosis. Hypertension 38: 635-638, 2001.
25. Molkentin JD, Lu JR, Antos CL, Markham B, Richardson J, Robbins J, Grant SR, Olson EN. A calcineurin-dependent transcriptional pathway for cardiac hypertrophy. Cell 93: 215-228, 1998.
26. Nam TS, Choi SH, Rah SY, Kim SY, Jang W, Im MJ, Kwon HJ, Kim UH. Discovery of a small-molecule inhibitor for kidney ADP-ribosyl cyclase: Implication for intracellular calcium signal mediated by cyclic ADP-ribose. Exp Mol Med 38: 718-726, 2006.
27. Northrop JP, Ho SN, Chen L, Thomas DJ, Timmerman LA, Nolan GP, Admon A, Crabtree GR. NF-AT components define a family of transcription factors targeted in T-cell activation. Nature 369: 497-502, 1994.
28. Partida-Sanchez S, Cockayne DA, Monard S, Jacobson EL, Oppenheimer N, Garvy B, Kusser K, Goodrich S, Howard M, Harmsen A, Randall TD, Lund FE. Cyclic ADP-ribose production by CD38 regulates intracellular calcium release, extracellular calcium influx and chemotaxis in neutrophils and is required for bacterial clearance in vivo. Nat Med 7: 1209 -1216, 2001.
29. 2+ level and motility of lymphokine-activated killer cells. J Biol Chem 280: 2888-2895, 2005.
30. Ranger AM, Grusby MJ, Hodge MR, Gravallese EM, de la Brousse FC, Hoev T, Mickanin C, Baldwin HS, Glimcher LH. The transcription factor NF-ATc is essential for cardiac valve formation. Nature 392: 186-190, 1998.
31. Rao A, Luo C, Hogan PG. Transcription factors of the NF-AT family: regulation and function. Annu Rev Immunol 15: 707-747, 1997.
32. Ruiz-Torres MP, Lopez-Ongil S, Griera M, Diez-Marques ML, Rodriguez-Puyol M, Rodriguez-Puyol D. The accumulation of extracellular matrix in the kidney: consequences on cellular function. J Nephrol 18: 334-340, 2005.
33. Shi S, Zheng S, Zhu Y, Jia C, Xie H. Inhibitory effect of tea polyphenols on renal cell apoptosis in rat test subjects suffering from cyclosporine-induced chronic nephrotoxicity. Chin Med J 116: 1345-1350, 2003.
34. Suzuki K, Han DG, Miyauchi N, Hashimoto T, Nakatsue T, Fujioka Y, Koike H, Shimizu F, Kawachi H. Angiotensin II type 1 and type 2 receptors play opposite roles in regulating the barrier function of kidney glomerular capillary wall. Am J Pathol 170: 1841-1853, 2007.
35. Vestra MD, Sailer A, Mauer M, Fioretto P. Role of mesangial expansion in the pathogenesis of diabetic nephropathy. J Nephrol 14: S51-S57, 2001.
36. Ziyadeh FN, Sharma K, Ericksen M, Wolf G. Stimulation of collagen gene expression and protein synthesis in murine mesangial cells by high glucose is mediated by autocrine activation of transforming growth factor-beta. J Clin Invest 93: 536-542, 1994.